Association of ESR1 Mutations and Visceral Metastasis in Patients with Estrogen Receptor-Positive Advanced Breast Cancer from Brazil
Joint Authors
Reinert, Tomás
Coelho, Guilherme Portela
Mandelli, Jovana
Zimermann, Edinéia
Zaffaroni, Facundo
Bines, José
Barrios, Carlos Henrique
Graudenz, Marcia Silveira
Source
Issue
Vol. 2019, Issue 2019 (31 Dec. 2019), pp.1-5, 5 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2019-08-14
Country of Publication
Egypt
No. of Pages
5
Main Subjects
Abstract EN
Mutations in the ESR1 gene (ESR1m) are important mechanisms of resistance to endocrine therapy in estrogen receptor-positive advanced breast cancer and have been recognized as a prognostic and predictive biomarker as well as a potential therapeutic target.
However, the prevalence of ESR1m in real-world patients has not been adequately described.
Therefore, we sought to evaluate the prevalence of ESR1m in metastatic samples from Brazilian patients with estrogen receptor-positive (ER+) advanced breast cancer previously treated with endocrine therapy.
The presence of ESR1m was evaluated in formalin-fixed paraffin-embedded (FFPE) breast cancer tissue using real-time quantitative polymerase chain reaction (RT-qPCR).
Mutations in codons 380, 537, and 538 of the ESR1 gene were analyzed.
Out of 77 breast cancer samples, 11 (14.3%) showed mutations in the ESR1 gene.
ESR1m were detected in a variety of organs, and the D538G substitution was the most common mutation.
In visceral metastasis, ESR1m were detected in 25% (8/32) of the samples, whereas in nonvisceral metastasis, ESR1m were detected in 6.7% (3/45) of the samples.
The odds of a sample with visceral metastasis having an ESR1 mutation is 4.66 times the odds of a sample of nonvisceral metastasis having an ESR1 mutation (95% CI: 1.13–19.27; p value = 0.0333).
Our study indicates that the prevalence of ESR1m in samples from Brazilian patients with metastatic ER+ breast cancer is similar to that described in patients included in clinical trials.
We observed an association of ESR1m with visceral metastasis.
American Psychological Association (APA)
Reinert, Tomás& Coelho, Guilherme Portela& Mandelli, Jovana& Zimermann, Edinéia& Zaffaroni, Facundo& Bines, José…[et al.]. 2019. Association of ESR1 Mutations and Visceral Metastasis in Patients with Estrogen Receptor-Positive Advanced Breast Cancer from Brazil. Journal of Oncology،Vol. 2019, no. 2019, pp.1-5.
https://search.emarefa.net/detail/BIM-1183993
Modern Language Association (MLA)
Reinert, Tomás…[et al.]. Association of ESR1 Mutations and Visceral Metastasis in Patients with Estrogen Receptor-Positive Advanced Breast Cancer from Brazil. Journal of Oncology No. 2019 (2019), pp.1-5.
https://search.emarefa.net/detail/BIM-1183993
American Medical Association (AMA)
Reinert, Tomás& Coelho, Guilherme Portela& Mandelli, Jovana& Zimermann, Edinéia& Zaffaroni, Facundo& Bines, José…[et al.]. Association of ESR1 Mutations and Visceral Metastasis in Patients with Estrogen Receptor-Positive Advanced Breast Cancer from Brazil. Journal of Oncology. 2019. Vol. 2019, no. 2019, pp.1-5.
https://search.emarefa.net/detail/BIM-1183993
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-1183993